Expected Results with Semaglutide Most patients experience measurable weight reduction within the first four weeks of treatment
Higher concentrations risk precipitation (the peptide falling out of solution) and make low doses difficult to measure
Its generally safe for healthy adults when administered by qualified providers
To align with FDA and FTC guidelines, please note: Peptides do not diagnose, treat, cure, or prevent disease
Hormonal Rebalancing With weight loss, oestrogen and other hormone-producing adipose tissue decreases, leading to a new body equilibrium with lower oestrogen levels
Many patients starting GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) wonder about this potential side effect